PHR: JP Morgan Lowers Price Target, Maintains Overweight Rating
JP Morgan has lowered its price target for Phreesia (PHR) from $29.00 to $24.00, while maintaining an "Overweight" rating. This adjustment follows several other analysts who have also reduced their price targets for PHR recently, though generally maintaining positive ratings. Despite these adjustments, the average target price from Wall Street analysts suggests a significant upside of 125.42% from its current price, and GuruFocus estimates an even higher fair value for the stock.
Phreesia Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of investors in Phreesia, Inc. (NYSE: PHR) following a significant 25% drop in stock price on December 9, 2025. The investigation focuses on whether Phreesia's executive officers complied with federal securities laws, stemming from updated fiscal 2026 revenue guidance during an earnings call. Shareholders who suffered losses are encouraged to contact Johnson Fistel for more information about potentially recovering their investments.
Phreesia Sets Release Date for Fiscal Fourth Quarter and Fiscal Year 2026 Results
Phreesia, Inc. announced that it will release its fiscal fourth quarter and fiscal year 2026 financial results after market close on Monday, March 30, 2026. The company will also hold a conference call and webcast on the same day at 5 PM Eastern Time to discuss these results. Details for accessing the press release, stakeholder letter, and the call are available on Phreesia's investor website.
Market Cool On Phreesia, Inc.'s (NYSE:PHR) Revenues Pushing Shares 27% Lower
Phreesia, Inc. (NYSE:PHR) shares have dropped 27% in the last month, contributing to a 56% loss over the past year. Despite a low price-to-sales (P/S) ratio of 1.6x compared to the industry average, and revenue growth that aligns with or exceeds industry forecasts, shareholders remain cautious. This suggests investors are doubtful about future revenue stability, possibly due to perceived risks.
Phreesia Data Breach Investigation
Strauss Borrelli PLLC is investigating a data breach at Phreesia, Inc. that exposed sensitive personal and protected health information. The breach, which Phreesia discovered on August 25, 2025, involved a third-party software tool called Salesloft Drift and potentially compromised names, Social Security numbers, dates of birth, and medical information. Affected individuals are being offered 24 months of complimentary credit monitoring services.
Vanguard Group Inc's Strategic Acquisition of Phreesia Inc Shares
Vanguard Group Inc. recently increased its stake in Phreesia Inc. by acquiring 338,828 shares at $13.43 each, bringing its total to over 6 million shares. This move highlights Vanguard's confidence in Phreesia's long-term growth potential, despite the healthcare software company's recent stock price decline and undervaluation according to GF Valuation. Phreesia Inc. shows promising revenue and EBITDA growth, aligning with Vanguard's strategy of investing in undervalued companies within the healthcare technology sector.
Phreesia CEO Chaim Indig Named to The Software Report’s Top 50 CEOs of 2025
Chaim Indig, CEO and co-founder of Phreesia, has been recognized for the third time on The Software Report’s Top 50 CEOs of 2025 list. This award acknowledges leaders who deliver value to customers and lead strong, mission-driven software organizations, based on nominations from industry peers. Under Indig's leadership since 2005, Phreesia has become a publicly traded SaaS company, supporting over 4,400 healthcare organizations and enabling approximately 170 million patient visits in 2024.
Phreesia (NYSE:PHR) Rating Lowered to Buy at Wall Street Zen
Wall Street Zen downgraded Phreesia (NYSE:PHR) from a "strong-buy" to a "buy" rating, although the average analyst rating remains a "Moderate Buy" with a target price of $29.41. The company's stock opened down 2.9% at $12.22, with a market capitalization of $736.7 million. Despite reporting a revenue increase of 12.7% to $120.3 million and an EPS beat in its latest quarter, Phreesia remains unprofitable and analysts forecast a negative EPS for the current year.
Waystar Weighs AI Growth Potential Against Rising Balance Sheet Risk
Waystar Holding Corp. is leveraging AI to drive growth in the healthcare software sector, but its recent acquisition of Iodine Software has raised concerns about its balance sheet due to increased debt. The article compares Waystar to competitors Phreesia and Doximity, highlighting Phreesia's recent GAAP profitability and Doximity's strong revenue growth, while noting that all three companies have experienced share price declines despite positive analyst outlooks. The analysis suggests investors should consider both growth potential and financial risks when evaluating these companies in the competitive AI and cloud healthcare market.
Can Waystar Still Stand Up to Rising Competition?
Waystar Holding Corp. faces increasing competition in the crowded healthcare AI and cloud computing sector, with its shares down 40% in the last year, despite analyst predictions of growth. The article compares Waystar with rivals Phreesia Inc. and Doximity Inc., highlighting Waystar's AI developments and growth balanced against balance sheet risks associated with its recent acquisition. Both Phreesia and Doximity also show promising growth trajectories and strong balance sheets respectively, even with recent stock declines and broader sector concerns.
DA Davidson lowers Phreesia stock price target to $30 on growth outlook By Investing.com
DA Davidson has lowered its price target for Phreesia Inc. (NYSE: PHR) to $30 from $35 but maintained a Buy rating, viewing the recent stock underperformance as a "buying opportunity." This adjustment follows discussions about the company's long-term growth drivers that could exceed its fiscal year 2027 revenue guidance. The new target represents significant upside potential from Phreesia's current trading price.
Phreesia price target lowered to $30 from $35 at DA Davidson
DA Davidson has reduced its price target for Phreesia (PHR) from $35 to $30, while maintaining a Buy rating. The firm remains constructive on Phreesia's FY27 outlook after discussing long-term growth drivers with the company, noting that recent stock underperformance presents a buying opportunity. The analyst believes these drivers could lead to upside against the 8-10% organic year-over-year revenue growth guidance for FY27.
DA Davidson Lowers Price Target for Phreesia (PHR) to $30.00 | P
DA Davidson has reaffirmed its "Buy" rating for Phreesia (PHR) but lowered its price target from $35.00 to $30.00, a 14.29% reduction. This adjustment follows several other analysts who have also recently revised their price targets for the healthcare software provider. Despite the lower target, the average analyst forecast for PHR suggests a significant upside from its current price.
DA Davidson lowers Phreesia stock price target to $30 on growth outlook
DA Davidson has lowered its price target for Phreesia Inc. (NYSE:PHR) to $30 from $35, while reiterating a Buy rating. The adjustment follows discussions with Phreesia's CFO regarding long-term growth drivers and comes despite a "constructive view" on the company's fiscal year 2027 outlook, with DA Davidson characterizing the recent stock underperformance as a "buying opportunity." Other analysts have offered mixed views, with Raymond James and Mizuho also adjusting targets downwards, while Wells Fargo and Piper Sandler initiated positive coverage.
DA Davidson lowers Phreesia stock price target to $30 on growth outlook
DA Davidson has lowered its price target for Phreesia Inc. (NYSE:PHR) to $30 from $35 but maintained a "Buy" rating, viewing the current stock price as an attractive buying opportunity. The adjustment follows discussions about the company's long-term growth prospects, which are expected to exceed its 2027 revenue guidance. Other analysts have a mixed view, with some reiterating Buy ratings and others lowering price targets based on varying financial outlooks.
Insider Selling: Phreesia (NYSE:PHR) General Counsel Sells 3,995 Shares of Stock
Phreesia's General Counsel, Allison Hoffman, sold 3,995 shares of the company's stock for $65,358.20, reducing her position by 2.3%. This insider selling occurred despite Phreesia beating recent earnings expectations, though the company still faces a negative net margin and analysts project a negative EPS for the current year. Currently trading near its one-year low, the stock has a consensus "Moderate Buy" rating and a price target significantly higher than its current trading price.
Insider Selling: Phreesia (NYSE:PHR) Insider Sells 6,038 Shares of Stock
Phreesia insider David Linetsky sold 6,038 shares of the company's stock on January 16th at an average price of $16.36, decreasing his ownership by 2.63%. This is part of a series of recent insider sales by Linetsky. Phreesia (NYSE: PHR) recently reported strong quarterly earnings, beating EPS estimates and growing revenue by 12.7% year-over-year, and analysts maintain a "Moderate Buy" rating with a consensus price target of $30.06.
Phreesia (NYSE:PHR) Insider Sells $102,544.48 in Stock
Phreesia insider Evan Roberts sold 6,268 shares of PHR stock for $102,544.48 on January 16th, reducing his stake by 0.75%. This transaction follows other recent sales by Roberts. The healthcare IT company's stock currently trades at $15.76, below its moving averages, despite topping recent quarterly earnings estimates.
Phreesia (NYSE:PHR) Sets New 52-Week Low on Insider Selling
Phreesia (NYSE:PHR) recently hit a new 52-week low following coordinated insider selling by several senior executives, including the CFO and General Counsel, in mid-January. Despite this, analysts remain largely positive on the stock, with a "Moderate Buy" consensus and an average price target significantly above current trading levels. The company also reported strong quarterly results with a revenue increase of 12.7% year-over-year and an EPS beat, supporting its growth narrative.
Balaji Gandhi Sells 975 Shares of Phreesia (NYSE:PHR) Stock
Phreesia CFO Balaji Gandhi recently sold 975 shares of the company's stock on January 15th for approximately $15,970, reducing his total holdings to 155,256 shares (a 0.62% decrease). This transaction is part of a series of recent sales by Gandhi, including 4,687 shares on January 16th and 8,009 shares on January 8th. Despite these insider sales and the stock trading below its moving averages, analysts maintain a "Moderate Buy" rating with an average target price of $30.06.
Phreesia (NYSE:PHR) General Counsel Sells $18,116.28 in Stock
Phreesia's General Counsel, Allison Hoffman, sold 1,106 shares of PHR stock for $18,116.28 on January 15th, reducing her position by 0.63%. The sale follows Phreesia beating its quarterly EPS expectations with $0.10 against an estimated -$0.01 and achieving $120.33 million in revenue. The company maintains a "Moderate Buy" consensus rating from analysts with an average target price of $30.06.
Phreesia (NYSE:PHR) CFO Sells $76,679.32 in Stock
Phreesia (NYSE:PHR) CFO Balaji Gandhi sold 4,687 shares of the company's stock on January 16th for $76,679.32, reducing his stake by 3.02%. This transaction follows other recent sales by Gandhi on January 8th and 15th, indicating a pattern of insider selling. Despite these insider sales, analysts maintain a "Moderate Buy" consensus for Phreesia, with an average price target of $30.06, following a recent earnings report that beat estimates.
Phreesia CEO Indig sells shares worth $206,704
Phreesia CEO Chaim Indig sold a total of 12,633 shares of the company's common stock across two transactions on January 15 and 16, 2026, totaling $206,704. These sales occurred with the stock trading near its 52-week lows. Analysts expect Phreesia to be profitable this year, and the company maintains a strong financial position, though some firms have adjusted price targets based on recent performance guidance.
Phreesia CEO Indig sells shares worth $206,704
Phreesia, Inc. CEO Chaim Indig sold a total of 12,633 shares of the company's common stock on January 15 and 16, 2026, amounting to $206,704. Despite the company not being profitable over the last year, an InvestingPro analysis suggests the stock is currently undervalued. This insider transaction comes amidst varying analyst perspectives on Phreesia's financial outlook, with some firms reiterating "Buy" ratings and others lowering price targets.
Phreesia (NYSE:PHR) Insider David Linetsky Sells 1,743 Shares
Phreesia (NYSE:PHR) insider David Linetsky sold 1,743 shares of the company's stock on January 15th at an average price of $16.38, totaling $28,550.34. This sale was part of a series of transactions between December 17th and January 16th, where Linetsky sold a total of 13,981 shares for approximately $233,000. Following the most recent sale, Linetsky still owns 229,980 shares of Phreesia, valued at over $3.7 million.
Phreesia, Inc. (PHR) Stock Analysis: Strong Buy Ratings And A 77.90% Potential Upside
Phreesia, Inc. (PHR) stock, a healthcare technology company, shows a significant 77.90% potential upside according to analysts, with all 20 ratings being "buy." Despite currently trading at the lower end of its 52-week range and operating at a loss, the company exhibits strong revenue growth and positive free cash flow. Investors may find Phreesia an attractive option due to its strategic market positioning, diverse solutions, and growth prospects in the healthcare sector.
Phreesia (NYSE:PHR) SVP Amy Beth Vanduyn Sells 2,202 Shares
Phreesia (NYSE:PHR) SVP Amy Beth Vanduyn recently sold 2,202 shares of the company's stock on January 16th, 2026, for approximately $36,024. This transaction reduced her stake by 1.38% to 157,349 shares, following other sales earlier in the month. Phreesia's stock is currently trading near its 1-year low, despite a recent quarterly earnings beat and positive revenue growth.
Hui Yvonne of Phreesia sells $12,098 in shares By Investing.com
Yvonne Hui, Principal Accounting Officer at Phreesia, Inc., sold a total of 744 shares for approximately $12,098 in two separate transactions in January 2026. These sales were made to cover tax obligations and under a pre-arranged trading plan. Despite not being profitable in the last twelve months, analysts predict profitability this year and consider the stock undervalued, with various firms maintaining differing price targets.
Hui Yvonne of Phreesia sells $12,098 in shares By Investing.com
Yvonne Hui, Principal Accounting Officer at Phreesia, Inc. (NASDAQ:PHR), sold 744 shares of common stock across two transactions for a total of $12,098. These sales were made to cover tax obligations and under a pre-arranged trading plan.
Hui Yvonne of Phreesia sells $12,098 in shares By Investing.com
Yvonne Hui, Phreesia's Principal Accounting Officer, sold a total of 744 shares of common stock across two transactions, amounting to approximately $12,098. These sales were made to cover tax obligations related to restricted stock units and as part of a pre-arranged trading plan. Despite the sales, analysts predict profitability for Phreesia this year, and the company maintains a strong financial position, with varied analyst ratings from Buy to Overweight.
FMR LLC Reduces Stake in Phreesia Inc: A Strategic Portfolio Adjustment
FMR LLC, also known as Fidelity, has reduced its stake in Phreesia Inc by selling over 3.5 million shares at $16.92 each, retaining 362,971 shares in the healthcare software company. This transaction, executed on December 31, 2025, represents a strategic portfolio adjustment. Phreesia Inc, despite being considered "significantly undervalued" with robust financial strength and growth metrics, shows challenges in profitability, prompting the firm's reallocation of resources.
Balaji Gandhi Sells 8,009 Shares of Phreesia (NYSE:PHR) Stock
Phreesia CFO Balaji Gandhi sold 8,009 shares of PHR stock on January 8th for approximately $136,233, reducing his stake by 4.88%. The company recently exceeded earnings per share and revenue estimates but analysts still project a negative EPS for the current year. Despite price target reductions from some analysts, the consensus rating for Phreesia remains a "Moderate Buy" with a target price of $30.06.
Phreesia, Inc. (PHR) Investor Outlook: A 70% Potential Upside in the Healthcare SaaS Space
Phreesia, Inc. (PHR) shows a potential upside of over 70% with a target price of $29.16, despite its current stock price of $17.14 being near its 52-week low. Analysts have a unanimous "buy" rating for the healthcare SaaS provider, which boasts impressive revenue growth of 45.70% and robust free cash flow, though it is not yet profitable. The company's strategic positioning with comprehensive software solutions aims to streamline healthcare interactions for both providers and patients.
Phreesia (NYSE:PHR) SVP Amy Beth Vanduyn Sells 2,602 Shares
Phreesia (NYSE:PHR) SVP Amy Beth Vanduyn sold 2,602 shares of the company's stock on January 8th at an average price of $17.01, reducing her total holdings by 1.6% to 160,238 shares. The company recently reported better-than-expected EPS of $0.10 and revenue of $120.33 million, though it remains unprofitable with a negative net margin and ROE. Institutional investors hold a significant portion of Phreesia's stock, and analysts maintain a "Moderate Buy" rating with a consensus price target of $30.06.
David Linetsky Sells 6,106 Shares of Phreesia (NYSE:PHR) Stock
David Linetsky, an insider at Phreesia (NYSE:PHR), sold 6,106 shares of the company's stock on January 8th at an average price of $17.01, totaling approximately $103,863. This transaction reduced his holding by 2.57% to 231,723 shares. Phreesia recently reported strong quarterly earnings, beating EPS estimates, and analysts maintain a "Moderate Buy" consensus rating with a target price of $30.06.
Phreesia (NYSE:PHR) Stock Rating Upgraded by Wells Fargo & Company
Wells Fargo & Company upgraded Phreesia (NYSE:PHR) to a "strong-buy" rating. Despite beating quarterly estimates with $0.10 EPS and a 12.7% revenue increase to $120.33 million, Phreesia remains unprofitable with analysts forecasting -1.1 EPS for the current fiscal year. The stock has an average rating of "Moderate Buy" and a consensus price target of $30.06 among analysts.
Wells Fargo initiates Phreesia stock with Overweight rating, $30 price target
Wells Fargo has initiated coverage on Phreesia Inc. (NYSE:PHR) with an Overweight rating and a $30 price target, citing the company's strong position in managing patient intake, scheduling, and payments across 14% of U.S. patient visits. Despite trading below its 2019 IPO price, Phreesia has nearly quadrupled revenue since then and dramatically improved its adjusted EBITDA margins. Other analysts have provided mixed assessments, with some reiterating buy ratings and higher price targets, while others have lowered price targets due to conservative revenue outlooks.
Wells Fargo Initiates Coverage on Phreesia (PHR) with Overweight Rating | PHR Stock News
Wells Fargo has initiated coverage on Phreesia (PHR) with an Overweight rating and set a price target of USD 30.00. This new assessment follows a period of adjusted price targets from other institutions. Phreesia, a provider of healthcare software solutions, receives continued analyst attention as the market anticipates its future performance, with Wall Street analysts forecasting an average target price of $29.82.
Wells Fargo initiates Phreesia stock with Overweight rating, $30 price target
Wells Fargo has initiated coverage on Phreesia Inc. (NYSE:PHR) with an Overweight rating and a $30 price target, citing the company's strong position in managing patient intake, scheduling, and payments across 14% of U.S. patient visits. Despite trading below its 2019 IPO price, Phreesia has nearly quadrupled revenue and dramatically improved its adjusted EBITDA margins. The bank anticipates upcoming fiscal third-quarter 2026 earnings to reset estimates and drive upward stock momentum.
Could Phreesia’s Stock Be Set for a Better Year? Stephens Adds To Best Ideas List
Phreesia Inc. (NYSE: PHR) has been added to Stephens' "Best Ideas" list for 2026, suggesting a potential turnaround after a challenging 2025 where its stock declined by over 32%. Despite positive signs like a 13% year-over-year revenue increase in its latest fiscal quarter and strategic acquisition of AccessOne, the company faces headwinds including disappointing revenue guidance and regulatory scrutiny. The article highlights both the bullish and bearish arguments, emphasizing that the interplay of these factors will dictate Phreesia's future trajectory.
Phreesia, Inc. (NYSE:PHR) Given Average Recommendation of "Moderate Buy" by Brokerages
Eighteen brokerages have given Phreesia, Inc. (NYSE:PHR) an average "Moderate Buy" rating, with a consensus one-year price target of $31.00. Despite beating recent earnings expectations, the company remains unprofitable, and insiders have sold shares while institutional investors hold a significant stake. The stock is currently trading around $16.91, well below the average analyst target.
Phreesia Cracks Top 10 as Software Recognition Signals Healthcare AI Momentum
Phreesia (NYSE: PHR) has achieved a Top 10 ranking on The Software Report’s Top 50 Software Companies of 2025, marking its fourth consecutive appearance and its highest position yet. This recognition underscores the company's innovation in healthcare technology, particularly with the introduction of Phreesia VoiceAI, which aims to simplify patient and provider experiences. The achievement highlights the growing importance of digital tools and conversational automation in streamlining healthcare operations and improving patient engagement.
Phreesia Inc (NYSE:PHR) Swings to Profit, Raises Outlook on AccessOne Deal
Phreesia Inc. reported a significant swing to profitability in its fiscal third quarter, driven by strong operating leverage, and raised its financial outlook for fiscal years 2026 and 2027. This improved forecast is largely due to the recent acquisition of AccessOne, a patient financing solution provider. Despite the positive financial results, the market's initial reaction was muted, with shares trading slightly lower in after-hours activity.
Capricorn Fund Managers Ltd Takes Position in Phreesia, Inc. $PHR
Capricorn Fund Managers Ltd has acquired a new position in Phreesia, Inc. (NYSE:PHR), purchasing 484,500 shares valued at approximately $11.4 million, making it their 7th largest holding. Phreesia recently reported stronger-than-expected Q3 earnings and revenue, though it still faces negative net margins and projected negative EPS for the fiscal year. Institutional ownership of the stock is high at 92.1%, and analysts maintain a "Moderate Buy" rating with an average price target significantly above the current share price.
Phreesia Stock Has Been Crushed. We’re Standing By Our Pick.
Phreesia's stock has seen a significant downturn, but the author believes this presents a compelling buying opportunity. The article suggests that despite the poor performance, the company's valuation and growth prospects remain strong.
Phreesia Swings to Profit as Growth Accelerates and AccessOne Deal Lands
Phreesia, Inc. reported a significant financial turnaround in its fiscal third quarter, achieving profitability with $4.3 million in net income and strong cash generation. The healthcare technology company saw revenue climb 13 percent to $120.3 million, driven by client growth and increased revenue per customer. The company also completed its $160 million acquisition of AccessOne and raised its financial outlook for fiscal years 2026 and 2027, anticipating continued growth and operational efficiency.
Phreesia swings to profit as growth accelerates and AccessOne deal lands
Phreesia reported a swing to profitability, with strong revenue growth and an improved outlook. The company also announced the acquisition of AccessOne, enhancing its payment platform with patient financing solutions, and detailed several new client partnerships.
Phreesia Named to The Software Report’s “Top 50 Software Companies” for the Fourth Consecutive Year
Phreesia, a leader in patient intake, outreach, and activation, has been recognized by The Software Report as one of the "Top 50 Software Companies of 2025" for the fourth consecutive year. This year marks Phreesia's first time ranking among the Top 10, highlighting its product excellence, organizational strength, and significant impact on the software industry, particularly with innovations like Phreesia VoiceAI. The company continues its commitment to improving healthcare experiences for patients and providers.
Squarepoint Ops LLC Buys 71,553 Shares of Phreesia, Inc. $PHR
Squarepoint Ops LLC significantly increased its stake in Phreesia, Inc. (NYSE:PHR) during Q2, purchasing 71,553 additional shares to bring its total holdings to 100,922 shares valued at $2.87 million. Other institutional investors also boosted their positions in the healthcare IT company, which saw insider selling over the past three months. Analysts maintain a "Moderate Buy" rating with a consensus price target of $31.00, despite the company trading around $16.28 and reporting negative margins, though it did beat quarterly earnings expectations.
BMO Capital Sticks to Its Buy Rating for Phreesia (PHR)
BMO Capital analyst Sean Dodge has maintained a Buy rating on Phreesia (PHR) with a price target of $32.00, despite the stock closing at $16.25 the previous day. The company reported improved financial results for the quarter ending October 31, with increased revenue and a net profit compared to a net loss in the prior year. However, corporate insider sentiment for PHR is negative, with an increase in insider selling over the past quarter.
